Reducing Repeat Biopsies
Supporting Timely Diagnosis
Rapid on-site evaluation (ROSE) is an established procedure where a Cytopathologist evaluates a biopsy specimen at the time of collection to determine if the content is adequate to provide a diagnosis. ROSE AId, a technology that digitizes and automates the ROSE process, can increase availability of ROSE in all healthcare settings resulting in a reduction in repeat biopsies, timelier diagnosis, and ultimately better outcomes.
Featured on AdvancementsTV
RoseAid was recently featured on AdvancementsTV which focuses on technologies and solutions dedicated to shaping, molding and transforming our world. Learn about our recent innovations in diagnostics technology!
The RoseAid segment is the first 7 minutes of the video.
Click Here to Watch
The Rose AId Solution
A diagnosis of cancer is typically made by a series of evaluations that progress in complexity. A patient presenting with symptoms will usually undergo a physician assessment followed by radiographic imaging of the affected area. If a suspicious mass is visualized the next least invasive step is to perform a needle biopsy to extract a sample of cells from the mass. Needle biopsies can be done directly through the skin or can be performed under ultrasound or endoscopic guidance depending on the location of the mass. Extracted biopsy samples are evaluated by a Cytopathologist who renders a diagnosis based on the types of cells identified in the sample.
Regardless of the method of collection, it is important to ensure that a needle biopsy specimen contains a sufficient number of cells from which the Cytopathologist can make a diagnosis. An inadequate sample usually will result in the need to repeat the biopsy. Repeat biopsies mean additional invasive procedures for patients, delayed diagnosis and treatment and increased cost to the healthcare system.
To ensure adequate biopsy sampling a procedure named “Rapid On-Site Evaluation (ROSE)” was developed. ROSE is performed at the time of biopsy collection and involves a Cytopathologist viewing the biopsy sample under a microscope to ensure the content is adequate for diagnosis. Despite the numerous benefits of ROSE there are staffing and logistical constraints to implementing it and as a result it is not performed in many organizations. The ROSE AId solution aims to automate and digitize the ROSE process so that ROSE can be performed more efficiently in all healthcare settings.
Rose AId Benefits
ROSE AId will support increased adoption of rapid on-site evaluation in all healthcare settings. Expected benefits include:
For Patients: Immediate assurance of adequacy provides the opportunity to reduce needle passes and associated complications, supports timely diagnosis and reduces the likelihood of repeat biopsies.
For Cytopathologists and Clinicians: Digitization and automation reduces travel, wait, and ROSE completion times providing increased time for additional value-added “top of license” activities.
For Healthcare Facilities: Timelier procedures and reduced likelihood of repeat biopsies supports optimal use of imaging facilities and the opportunity to conduct additional procedures.
For Healthcare Payers: Elimination of waste and costs associated with repeat procedures and delay of treatment due to delayed diagnosis.
Please contact us to arrange a demonstration
or trial of our solution.